Our mission
Our mission
Our strategy
Our presentations
Our videos
Our why
Value of medicines
Featured presentations
How to Kill The Conversation That Makes Innovation Possible.
What’s the big deal about cutting the top-selling drugs down to just being reasonably profitable?
How public funding, incentives, and private funding function together to enable all of us to get what we want: new medicines.
Who we are
Our team
Patient Advocate Action Collective
Our team
Life science builders
Supporters
Featured presentations
How to Kill The Conversation That Makes Innovation Possible.
What’s the big deal about cutting the top-selling drugs down to just being reasonably profitable?
How public funding, incentives, and private funding function together to enable all of us to get what we want: new medicines.
Patients
Help for patients
Take action
How-tos
Featured resources
I've received a bill for in-person care that I can't pay
I've received a bill for a medication that I can't pay
I need in-person care but can't pay for it
Policy
Our priorities
Our presentations
Value of medicines
Letters to Washington
Small Molecule R&D Parity
Our Webinars
News & updates
Research projects
Featured presentations
How to Kill The Conversation That Makes Innovation Possible.
What’s the big deal about cutting the top-selling drugs down to just being reasonably profitable?
How public funding, incentives, and private funding function together to enable all of us to get what we want: new medicines.
Out-of-Pocket Report
Become a First Responder & Thought Partner
First Person
Dad Was Hit With a Four-Figure Copay. Harbor Path Got Him the Drug For Free
First Person
Natalie Kostich
No items found.
Did you know?
Increasing out-of-pocket costs by just $10 per prescription causes a 33% rise in mortality because fewer patients take the drugs their doctors prescribe.
Source: National Bureau of Economic Research, https://www.nber.org/papers/w28439
Get involved
